1160950-99-1

Basic information

• Product Name: 3',6-dimethoxy-N-(8-methoxy-7-(5-methylcyclohex-2-enyloxy)-2-oxo-2H-chromen-3-yl)biphenyl-3-carboxamide
• Synonyms: 3',6-dimethoxy-N-(8-methoxy-7-(5-methylcyclohex-2-enyloxy)-2-oxo-2H-chromen-3-yl)biphenyl-3-carboxamide
• CAS NO: 1160950-99-1
• Molecular Weight: 541.601
• Mol File: 1160950-99-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3',6-dimethoxy-N-(8-methoxy-7-(5-methylcyclohex-2-enyloxy)-2-oxo-2H-chromen-3-yl)biphenyl-3-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3',6-dimethoxy-N-(8-methoxy-7-(5-methylcyclohex-2-enyloxy)-2-oxo-2H-chromen-3-yl)biphenyl-3-carboxamide(1160950-99-1)
• EPA Substance Registry System: 3',6-dimethoxy-N-(8-methoxy-7-(5-methylcyclohex-2-enyloxy)-2-oxo-2H-chromen-3-yl)biphenyl-3-carboxamide(1160950-99-1)

Safety Data

• Hazardous Substances Data: 1160950-99-1(Hazardous Substances Data)

Upstream product

• 1308888-99-4 3-(((benzyloxy)carbonyl)amino)-8-methoxy-2-oxo-2H-chromen-7-yl acetate 
• 1160952-27-1 N-(7-hydroxy-8-methoxy-2-oxo-2H-chromen-3-yl)-3',6-dimethoxy-[1,1'-biphenyl]-3-carboxamide 
• 3718-55-6 5-methyl-2-cyclohexen-1-ol 
• 1160952-43-1 3-(3',6-dimethoxy-[1,1'-biphenyl]-3-ylcarboxamido)-8-methoxy-2-oxo-2H-chromen-7-yl acetate 
• 1308889-59-9 C₁₂H₁₁NO₅ 
• 1083313-80-7 3',6-dimethoxy-[1,1'-biphenyl]-3-carbonyl chloride 
• 1083313-05-6 3′,6-dimethoxy-[1,1′-biphenyl]-3-carboxylic acid 
• 1083312-86-0 benzyl 7-hydroxy-8-methoxy-2-oxo-2H-chromen-3-ylcarbamate 
• 4341-24-6 5-methylcyclohexan-1,3-dione 

Relevant articles and documents

Engineering an antibiotic to fight cancer: Optimization of the novobiocin scaffold to produce anti-proliferative agents

Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplished through structural modifications to the amide side chain, coumarin ring, and sugar moiety. These species exhibit ?700- fold improved anti-proliferative activity versus the natural product as evaluated by cellular efficacies against breast, colon, prostate, lung, and other cancer cell lines. Utilization of structure- activity relationships established for three novobiocin synthons produced optimized scaffolds, which manifest midnanomolar activity against a panel of cancer cell lines and serve as lead compounds that manifest their activities through Hsp90 inhibition.